TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Renal fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Social Functioning as assessed by University of California, Los Angeles 3-point loneliness scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in Social Functioning as assessed by Facial Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in Social Functioning as assessed by a Social Functioning Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: COVID-19 Virus Detection in Tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID-19 Virus Detection in Nasopharyngeal Swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Freezing of gait Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for Primed up-and-go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for 10m walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overactive bladder (OAB) medication/treatment regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in mean scores of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mean scores of problem solving skills inventor
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Desirability of Outcome Ranking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response Adjusted for Duration of Antibiotic Risk-Score
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline daytime sleepness at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline quality of life at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline systolic blood pressure at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline inflammation at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone Width gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of motor rehabilitation course use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Redistribution of splanchnic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete Response (CR)
Endpoint domain: Adverse events/effects
Primary endpoint: Unacceptable Toxicity (UT)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of diagnosis of Narcolepsy Type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of diagnosis of Narcolepsy Type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive predictive value of diagnosis of Narcolepsy Type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative predictive value of diagnosis of Narcolepsy Type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of participants experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilation-perfusion matching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest radiograph findings in COVID-19 pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: wound failure with the development of incisional hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician assessed DAS-28 score for patients with rheumatoid arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician assessed PsARC score for patients with psoriatic arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Optimal Infant Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Adherence to HIV medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intra-reader Difference of Summed Rest Score (SRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra-reader Difference of Summed Rest Percent (SR%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percent Improvement From Baseline in PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diffusion-MRI based parameters of medial temporal lobe gray matter microstructure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Alcohol Use Disorders Identification Test (AUDIT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in stress and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent diet measured by Mediterranean Eating Pattern for Americans (MEPA) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in average pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vertical post-extraction resorption of the socket walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Assessment of Child Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Sleep Health
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Myopia screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women's interest in caesarean section
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of PrEP uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PrEP retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PrEP adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects with HbA1c ≤ 6.5% and free of severe hypoglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identify neuroinflammatory indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mood assessment through brain biomarker
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Investigation of the gut-brain-axis and of the biomarkers of interest in the context of mental diseases starting with MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Macrophages surrounding the sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MARD (CGM record for 10 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly mean 24-hour average pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intima-Media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse-Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Soft Tissue Contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Timed Up-and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Other arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3 or higher SBRT-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients meeting acceptability criteria for onco-sexology management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VR session completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EASI-75 at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IGA score at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: cerebral blood flow dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduced COVID-19 related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 24-hour glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: successful dural repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intra-operative CSF leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Masseteric trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum serum concentration) of TNB-738
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alertness time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Divided Attention time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Working Memory time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Documented Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of hematological remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mask exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAP Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Half-life time (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of Coronary Computerized Tomographic Angiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total norepinephrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Anastomotic Leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Hypersensitivity reaction (HSR) to Ultravist (iopromide)
Endpoint domain: Adverse events/effects
Primary endpoint: PTS at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of unacceptable adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Peripartum Hysterectomy Rate
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of grade 2 radiodermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with ASAS 40 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving clinical response (recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin safety assessed by adverse events of skin irritation and sensitization
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Margin Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biochemical Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: difference of arousal assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative seroconversion to all serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient pain during colonoscopy procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin reaction evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative delayed gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of fasted days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stigma change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Validation of PRESCIENT criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue sensitivity to insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain electrophysiological activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Temporal brain oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of decompensated cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Average change in Perceived Cognitive Impairment score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: All-cause explantation of the breast implant
Endpoint domain: Mortality/survival
Primary endpoint: Survival without adverse ophthalmological outcome
Endpoint domain: Mortality/survival
Primary endpoint: Monitoring performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of oral tinidazole for treatment of recurrent bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Efficacy of oral tinidazole for prevention of recurrent bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Scare burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation of Densitometric Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in the size of pseudomembranous conjunctival lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to change in the size of pseudomembranous lesions by 50% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the visual acuity of affected eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal to noise ratio of the MEG OPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal to noise ratio of HR EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dB between Signal to noise ratio of the MEG OPM and Signal to noise ratio of HR EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of participants with all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Change of Melasma Severity based on modified Melasma Severity Index (mMASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compare Quality Of Life based on MelasQoL Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Executive Cognitive Function (Working Memory)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients with sexual dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax of midazolam, s-warfarin, omeprazole, digoxin, rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of midazolam, s-warfarin, omeprazole, digoxin, rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of midazolam, s-warfarin, omeprazole, digoxin, rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of right ventricular end diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion of Study Measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ActiGraph Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Actigraph Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric Mean Titers of Prefusion F-protein Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prostate specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Subjective Pain Perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: International Hip Outcome Tool (iHOT-33)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnostic accuracy for acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Painless Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated tennis elbow evaluation (PRTEE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity (Neutralizing Antibody)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of ENS-002
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of ENS-002
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of biochemical progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Level of plasma neurofilament light chain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Achievement of >= 5% weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with adverse events (AE) or serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically meaningful change from baseline in laboratory tests results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events grade 2 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Time to reach maximum observed concentration (tmax) of AZD8630
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum (peak) drug concentration (Cmax) of AZD8630
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of the need for SoC 2-stage exchange arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intradialytic hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in hepatic MRglu (metabolic rate of glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of non-infectious diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operationalization
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Time required to implement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety participation
Endpoint domain: Adverse events/effects
Primary endpoint: NRS (Numerical rating scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cervical range of motion (degree)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bournemouth Neck Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cervical sagittal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial distress syndrome response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cumulative nonrecurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in perceptually rated accuracy of /r/
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer ablation efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of the severity of IBS-C symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postoperative recurrence of primary colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Cmax of sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the DEN vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vein diameter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of robotics testing activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes